You are here

RNAi

Bayer helps Harvard spinout Vesigen to $28.5M series A

Bayer helps Harvard spinout Vesigen to $28.5M series A

Fierce Biotech

Vesigen Therapeutics

Flag link:

Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show

Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show

Fierce Pharma

acute hepatic porphyria

Flag link:

Dicerna nabs speedy review voucher for leading RNAi drug

Dicerna nabs speedy review voucher for leading RNAi drug

Fierce Biotech

priority review

Flag link:

Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data

Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data

Endpoints

clinical trials

Flag link:

Alnylam nabs speedy review, setting up 3rd possible approval in 3 years

Alnylam nabs speedy review, setting up 3rd possible approval in 3 years

Endpoints

Flag link:

Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral

Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral

Fierce Biotech

Vir Biotechnology

clinical trials

Flag link:

Alnylam's vutrisiran gets fast-track treatment at the FDA

Alnylam's vutrisiran gets fast-track treatment at the FDA

Fierce Biotech

Flag link:

Blackstone backs Alnylam with up to $2B investment

Blackstone backs Alnylam with up to $2B investment

BioPharma Dive

Flag link:

Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis

Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis

Pharmaceutical Business Review

Arrowhead Pharmaceuticals

clinical trials

cystic fibrosis

Flag link:

After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration

After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration

Endpoints

John Maraganore

Douglas Fambrough

Flag link:

Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19

Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19

Pharmaceutical Business Review

Vir Biotechnology

drug development

Flag link:

Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)

Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)

Pharmaceutical Business Review

hATTR amyloidosis

Flag link:

Alnylam, Vir team up to develop siRNAs to tackle COVID-19

Alnylam, Vir team up to develop siRNAs to tackle COVID-19

Fierce Biotech

Vir Biotechnology

Flag link:

After big year, RNAi drugmakers compete to prove what comes next

After big year, RNAi drugmakers compete to prove what comes next

BioPharma Dive

Arrowhead Pharmaceuticals

Dicerna Pharmaceuticals

Flag link:

JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval

JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval

Fierce Pharma

John Maraganore

Flag link:

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

Biopharma Dive

clincial trials

Primary Hyperoxaluria

Flag link:

3 Soaring Biotech Stocks to Watch in December

3 Soaring Biotech Stocks to Watch in December

Motley Fool

Arrowhead Pharmaceuticals

Adverum Biotechnologies

Flag link:

Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class

Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class

Motley Fool

Flag link:

FDA's rapid review pace nets an early approval for Alnylam's second drug

FDA's rapid review pace nets an early approval for Alnylam's second drug

Biopharma Dive

Flag link:

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Endpoints

Flag link:

Pages